Archer is developing advanced materials to build disruptive technology, and these materials include carbon-based qubits for quantum computing, graphene enhanced biosensors, and graphitic battery anodes.
Our approach to materials development is enabling a new wave of converging technologies, each with the potential to positively impact global industries spanning electronics, medicine, and energy.
Quantum computing represents the next generation of powerful computing. A qubit processor is the most crucial hardware component of a quantum computer.
Archer is developing a qubit processor chip, that could potentially operate at room temperature and integrate into modern electronics.
Current quantum computing technologies are limited in ownership and use because they use qubit processors that can only operate at low temperatures and/or are difficult to integrate in modern electronics.
The successful development of Archer’s 12CQ room-temperature qubit processor chip could potentially provide a breakthrough solution to the widespread use and ownership of quantum computing powered technology, owing to the unique materials properties of the 12CQ chip.
The 12CQ qubit processor chip is being built by the Archer team in Sydney, Australia, in a world-class semiconductor foundry with an ISO Class 5 Level cleanroom housing state-of-art nanofabrication instrumentation. The work is led by Archer CEO and 12CQ inventor Dr Mohammad Choucair, and Archer’s Quantum Technology Manager Dr Martin Fuechsle, the inventor of the single-atom transistor. The 12CQ chip is based on work published in the prestigious journal Nature Communications, and patent application filed in Australasia, the EU, and US.
Australia has a critical mass of expertise in quantum computing and is at the forefront of the industry. There are currently very few publicly listed companies that offer exposure to financial returns from quantum computing technology.
The quantum computing industry forms a niche but quickly growing part of the global half-a-trillion-dollar semiconductor industry, which generates the highest value in investment returns through the step-change development of technology and underlying intellectual property.
Successful commercialisation of Archer’s 12CQ qubit processor chip technology could catalyse the global quantum computing industry by servicing existing and emerging consumer markets reliant on increased computational power like artificial intelligence (AI) and blockchain technologies like digital currencies.
Our strategy is to develop a qubit processor chip that can be directly sold and the intellectual property rights to the chip technology sublicensed by:
De-risking the technology by building a room-temperature operational qubit processor chip prototype. Development involves assembling and testing chip components by applying a deep understanding of nanotechnology, materials chemistry, and quantum physics.
Establishing partnerships with highly resourced organisations in the semiconductor industry. Commercial development involves prosecuting patent applications in Australasia, Europe and the US, to provide the commercial freedom to operate in these markets.
There is a global need for healthcare to become cheaper, efficient and more accessible. Printable biosensors could enable rapid and customised multi-disease detection and aid point of care disease management.
Wide-spread scalable and economically printed biosensing technologies are hindered by the difficulty to achieve both effective multi-functional disease detection and efficient process integration.
Archer is creating printable biosensors using graphene, the thinnest material known, to provide an ultrasensitive biochemical interface for multi-disease detection and compatibility with digitised processing for biosensor device integration.
We have invented highly processable graphene materials that allow for selective hierarchal chemistry to the single molecule level with the potential to solve selectivity and detection challenges for the wide-spread use of biosensors.
Archer has filed a provisional patent protecting this intellectual property (IP) and maintains 100% ownership of the IP. The biosensor technology is being developed at world-class institutes housing 2-D and 3-D prototype printing and testing facilities and instrumentation. The work is led by Archer CEO and inventor Dr Mohammad Choucair.
Australia has a critical mass of expertise in biotechnology and has made significant contributions to the industry. In Australia, Small-Medium-Enterprise companies could be eligible for a percentage cash refund of their annual R&D expenditure. There are currently about 150 publicly listed companies on the ASX in the Life Sciences sector.
The biosensing industry forms a niche but growing part of the global multibillion-dollar biotechnology industry, with established commercial pathways for high value investment returns through revenue generated from licensing of robust intellectual property portfolios.
Successful commercialisation of Archer’s graphene-based biosensor technology could catalyse the global biosensor industry by servicing the growing biomedical infrastructure of ageing populations in Europe, Australia, Asia, and the US, reliant on point-of-care health management.
Our strategy is to develop printable graphene-based biosensor componentry that can be patented and the intellectual property rights to the biosensor technology sublicensed by:
Developing a commercial prototype in-vitro diagnostic device by assembling and testing biosensor components that incorporate proprietary graphene-based biosensing technology capable of rapid multi-disease detection and device integration.
Establishing partnerships with highly resourced organisations in the biotechnology industry. Commercial development involves executing exclusive commercial partnership agreements while prosecuting patent applications in Australasia, Europe and the US.
Archer aims to participate in the integration of advanced materials in lithium-ion battery technologies that provide markets to underpin the development of our substantial graphite resources.
The potential for mobile technologies, including electric vehicles, to gain significant market share is dependent on reducing the relatively high cost of batteries compared to oil and gas.
The trade-off between cost and battery performance can be addressed fundamentally in two ways; decreasing costs by using cheaper materials and efficient processing; and/or improving battery performance through effective materials and formulations.
At Archer, we are formulating, building and testing batteries with a focus on addressing the trade-off between cost and battery performance using our significant Campoona graphite deposit (located in South Australia, Australia).
Our Campoona graphite has a high structural quality and purity, and an appropriate particle size and optimal morphology for effective lithium-ion battery integration.
We have successfully performed lab-scale development of our graphite materials using commercially relevant battery chemistries related to technologies for automotive applications and consumer electronics.
Archer has access to world-class battery testing and formulation facilities and instrumentation, where we generate value-add to Archer’s Campoona graphite development through the generation of intellectual property associated with reaching ultra-high graphite purities and materials for lithium-ion batteries with commercially relevant formulations.
Graphite materials, including spherical graphite, are a high-value materials entry point for the lithium-ion battery market which is forecast to increase to US$130 billion by 2028 with growth concentrated in the Asia Pacific region.
Lithium-ion batteries consist of a group of batteries which operate with graphite in the anode. Improvements in the anode are based on using graphite with high structural quality and purity, and an appropriate particle size and optimal morphology for effective lithium-ion intercalation chemistry.
Our work to date has definitively showed that Archer’s Campoona graphite is structurally near perfect to the atom-scale, can be processed into high value graphite materials, and can be used in conjunction with different types of lithium-ion batteries, potentially making it suitable for multiple battery markets.
Our strategy is to scale and integrate Campoona graphite products further downstream in the Li-ion battery supply chain by:
Investigating and testing the high value-added graphite materials products and processes, in full-scale lithium-ion batteries, to ensure we can meet minimum performance requirements and market accepted benchmarks.
Establishing a basic measure of commercial viability related to the efficient scaling of post-concentrate processes with industry partners for potential off-take agreements so that the project can be successfully developed to return maximum benefit to shareholders and the community.